Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jutta Hammermann"'
Autor:
Sivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner, Florian Stehling, Folke Brinkmann, Manuel Burkhart, Helmut Ellemunter, Anna-Maria Dittrich, Christina Smaczny, Olaf Eickmeier, Matthias Kappler, Carsten Schwarz, Sarah Sieber, Susanne Naehrig, Lutz Naehrlich, Klaus Tenbrock, Claus Pfannenstiel, Dirk Steffen, Jochen Meister, Britta Welzenbach, Anette Scharschinger, Markus Kratz, Maike Pincus, Tobias Tenenbaum, Mirjam Stahl, Kerstin Landwehr, Stefanie Dillenhöfer, Hans Kössel, Petra Kaiser, Manfred Käding, Simone Stolz, Stefan Blaas, Jutta Hammermann, Monika Gappa, Antje Schuster, Dana Spittel, Sabine Zirlik, Sabina Schmitt, Joachim Bargon, Malte Cremer, Sebastian Fähndrich, Andrea Heinzmann, Lutz Nährlich, Stefan Kuhnert, Sebastian Schmidt, Bettina Wollschläger, Anna Nolde, Inka Held, Wolfgang Kamin, Felix C. Ringshausen, Sabine Wege, Olaf Sommerburg, Norbert Geier, Sara Lisa Fleser, Heinrike Wilkens, Michael Lorenz, Paul Vöhringer, Martin Schebek, Christian Timke, Ingrid Bobis, Thomas Nüßlein, Doris Dieninghoff, Ernst Rietschel, Bastian Klinkhammer, Freerk Prenzel, Alexandra Wald, Axel Kempa, Eva Lücke, Ines Adams, Krystyna Poplawska, Simone Lehmkühler, Monika Bauck, Anne Pfülb, Rainald Fischer, Gudrun Schopper, Susanne Nährig, Matthias Griese, Jörg Grosse, Peter Küster, Birte KinderHolger Köster, Susanne Büsing, Margarethe Pohl, Andreas Artlich, Alexander Kiefer, Manfred Ballmann, Nikola Gjorgjevski, Markus A. Rose, Friederike Ruf, Rolf Mahlberg, Wolfgang Thomas, Ute Graepler, Sebastian Bode, hilipp Meyn, Josef Rosenecker, Cordula Koerner, Klaus-Michael Keller, Tina Teßmer, Helge Hebestreit, Gerhild Lohse
Publikováno v:
The Lancet Regional Health. Europe, Vol 32, Iss , Pp 100690- (2023)
Summary: Background: Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves multiple clinical outcomes in people with cystic fibrosis (pwCF) with at least one F508del allele. This study evaluated the real-world impact of ETI on lung function,
Externí odkaz:
https://doaj.org/article/cb7f1132ad9145b4909f1a838def4b95
Autor:
Corinna Westphal, Dennis Görlich, Stefanie Kampmeier, Susann Herzog, Nadja Braun, Carina Hitschke, Alexander Mellmann, Georg Peters, Barbara C. Kahl, Staphylococcal CF Study Group, Sibylle Junge., Burkhard Tümmler., Helmut Ellermunter, Angelika Dübbers, Peter Küster, Manfred Ballmann, Cordula Koerner-Rettberg, Jörg Große-Onnebrink, Eberhardt Heuer, Wolfgang Sextro, Jochen G, Jutta Hammermann, Ute Graepler-Mainka, Doris Staab, Bettina Wollschläger, Antje Schuster, Friedrich-Karl Tegtmeyer, Sivagurunathan Sutharsan, Alexandra Wald
Publikováno v:
Frontiers in Microbiology, Vol 11 (2020)
BackgroundStaphylococcus aureus is one of the most isolated pathogens from the airways of cystic fibrosis (CF) patients. There is a lack of information about the clonal nature of S. aureus cultured from CF patients and their impact on disease. We hyp
Externí odkaz:
https://doaj.org/article/984c7a7dfba141388d61877eb8766f77
Autor:
Olaf Sommerburg, Jutta Hammermann
Publikováno v:
International Journal of Neonatal Screening, Vol 6, Iss 2, p 28 (2020)
There are currently four countries and one local region in Europe that use PAP in their newborn screening programme. The first country to employ PAP at a national level was the Netherlands, which started using IRT/PAP/DNA/EGA in 2011. Germany followe
Externí odkaz:
https://doaj.org/article/0310d5ab66ce43018f4c5d54be10e735
Autor:
Mandy Sowa, Rafał Kolenda, Daniel C. Baumgart, Johann Pratschke, Maria Papp, Tamas Tornai, Jaroslaw Suchanski, Dimitrios P. Bogdanos, Maria G. Mytilinaiou, Jutta Hammermann, Martin W. Laass, Karsten Conrad, Christoph Schramm, Andre Franke, Dirk Roggenbuck, Peter Schierack
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Introduction: Zymogen granule glycoprotein 2 (GP2) was demonstrated as first autoimmune mucosal target in primary sclerosing cholangitis (PSC) associated with disease severity. Autoantibodies to four GP2 isoforms (aGP21−4) were found in patients wi
Externí odkaz:
https://doaj.org/article/de592f6e97cc47e4baf01a8c27da3d59
Autor:
Sibylle Junge, Dennis Görlich, Martijn den Reijer, Bärbel Wiedemann, Burkhard Tümmler, Helmut Ellemunter, Angelika Dübbers, Peter Küster, Manfred Ballmann, Cordula Koerner-Rettberg, Jörg Große-Onnebrink, Eberhardt Heuer, Wolfgang Sextro, Jochen G Mainz, Jutta Hammermann, Joachim Riethmüller, Ute Graepler-Mainka, Doris Staab, Bettina Wollschläger, Rüdiger Szczepanski, Antje Schuster, Friedrich-Karl Tegtmeyer, Sivagurunathan Sutharsan, Alexandra Wald, Jerzy-Roch Nofer, Willem van Wamel, Karsten Becker, Georg Peters, Barbara C Kahl
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0166220 (2016)
Staphylococcus aureus is an important pathogen in cystic fibrosis (CF). However, it is not clear which factors are associated with worse lung function in patients with persistent S. aureus airway cultures. Our main hypothesis was that patients with h
Externí odkaz:
https://doaj.org/article/2fd170f46763453f9678ccb54294c200
Autor:
Helge Hebestreit, Susi Kriemler, Christian Schindler, Lothar Stein, Chantal Karila, Don S. Urquhart, David M. Orenstein, Larry C. Lands, Jonathan Schaeff, Ernst Eber, Thomas Radtke, Marlies Wagner, Helmut Ellemunter, Nancy Alarie, Clotilde Simon, Anne Faucou, Laurent Mely, Bruno Ravaninjatovo, Anne Prevotat, Cordula Koerner-Rettberg, Jutta Hammermann, Christina Smaczny, Inka Held, Sibylle Junge, Oliver Nitsche, Rainald Fischer, Jörg Große-Onnebrink, Anne Wesner, Andreas Hector, Alexandra Hebestreit, Christian Benden, Carmen Casaulta, Reta Fischer, Alexander Möller, Erik Hulzebos, Marcella Burghard, Sarah Blacklock, Debbie Miller, Zoe Johnstone, John D. Lowman
Publikováno v:
2022, ' Effects of a partially supervised conditioning program in cystic fibrosis : an international multicenter randomized controlled trial (ACTIVATE-CF) ', American Journal of Respiratory and Critical Care Medicine, vol. 205, no. 3, pp. 330-339 . https://doi.org/10.1164/rccm.202106-1419OC
Rationale: The long-term effects of vigorous physical activity (PA) on lung function in cystic fibrosis are unclear. Objectives: To evaluate effects of a 12-month partially supervised PA intervention using motivational feedback. Methods: In a paralle
Autor:
John Tsanakas, I. Asherova, Olga Bede, Melinda Solomon, Gerhild Angyalosi, Jutta Hammermann, Katalin Bolbás, Robert Maykut, Michael Fayon, Elena Chertok, Martha L McKinney, Nipa Alon, Ferenc Gonczi, Felix Ratjen, Vladimir Bulatov, Anne Munck, Carla Colombo, Essam Gouda, Alexander Moeller
Publikováno v:
Journal of Cystic Fibrosis. 18:78-85
Antibiotic eradication treatment is the standard-of-care for cystic fibrosis (CF) patients with early Pseudomonas aeruginosa (Pa)-infection; however, evidence from placebo-controlled trials is limited.This double-blind, placebo-controlled trial rando
Autor:
Jochen G. Mainz, Uta Ceglarek, Jochen Meister, Constance Henn, Jutta Hammermann, Karin Thoss, Mandy Vogel, Franziska Duckstein, Julia Hentschel, Ulrike Issa, Ines Adams, Dana Spittel, Gerhild Lohse, Freerk Prenzel
Publikováno v:
Clinical chemistry and laboratory medicineReferences. 59(8)
Objectives Sweat chloride testing (SCT) is the mainstay for the diagnosis of cystic fibrosis (CF) and biomarker in the evaluation of CFTR-modifying drugs. To be a reliable and valid tool, analytical variance (CVA) must be minimized. However, external
Autor:
Ernst Rietschel, B. Schulte-Hubbert, R. Mahlberg, Carsten Schwarz, U. Düesberg, Michael Puderbach, F. Mattner, Christian Hügel, S. van Koningsbruggen-Rietschel, M. O. Wielpütz, C. Muche-Borowski, Ralf-Peter Vonberg, A. Möller, Helmut Ellemunter, Michael Hogardt, A. Koitschev, S. Illing, Jutta Hammermann, T. Nüßlein, S. Schmidt, D. Dieninghoff, H. Hebestreit, W. Bremer, Felix C. Ringshausen, Martin J. Hug, F. Brunsmann, Burkhard Tümmler, Helmut Sitter, Ingo Baumann, L. Sedlacek, B. Kahl, M. Abele-Horn, J. Grosse-Onnebrink, Rainald Fischer, J. Bend, H. Wilkens, A. Mehl, Andreas Jung, S. Renner, J. Zerlik, Olaf Eickmeier, B Wollschläger, Jochen G. Mainz, Christina Smaczny
Publikováno v:
Pneumologie. 72:347-392
ZusammenfassungMukoviszidose (Cystic Fibrosis, CF) ist die häufigste, autosomal-rezessiv vererbte Multisystemerkrankung. In Deutschland sind ca. 8000 Menschen betroffen. Die Erkrankung wird durch Mutationen im Cystic Fibrosis Transmembrane Conductan